Many disease-causing bacteria, viruses or fungi live on cloth, plastic and metal objects in your bathroom. Here's what you ...
HHS Secretary Robert F. Kennedy Jr.s CDC just funneled a $1.6 million dollar grant to researchers to carry out an unethical and scientifically unjustified randomized clinical trial of the birth dose o ...
Rutgers Health research confirms confusion about the different mechanisms that make tobacco addictive and deadly.
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
Study Finds on MSN
Menopause Hormone Therapy And Brain Health: What Research On 1 Million Women Tells Us
Review of 1 million women finds no clear link between hormone therapy and dementia risk. Evidence certainty is low with ...
Policy initiatives have come fast and furious at the FDA this year. While guidances on rare diseases and vaccines have consumed most of the ink, policy shifts aimed at improving FDA efficiencies and ...
This study provides important evidence that negative affect is associated with slower cognitive processing in daily life, with findings replicated across three independent samples and supported by ...
Morning Overview on MSN
New optics model reveals how polarized light moves through complex matter
Polarized light is one of the most powerful tools scientists have for peering inside matter, yet the way it twists, scatters ...
Curbed on MSN
The man who controls the lights at 270 Park Avenue
From this chilly vantage point, Villareal can see his monitor and also the top half of 270 Park Avenue, the new JPMorgan Chase tower. At dusk, he takes the controls. Villareal works principally in the ...
At the core of every AI coding agent is a technology called a large language model (LLM), which is a type of neural network ...
When AI-assisted coding is 20% slower and almost half of it introduces Top 10-level threats, it’s time to make sure we're not ...
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results